1. Scrip
  2. >>Business
  3. >>Earnings

Boehringer Looks To Revitalise Its Pipeline

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.    

Boehringer Ingelheim
• Source: Alamy

Boehringer Ingelheim GmbH hopes to launch 25 new drugs by 2030, and judging by its performance in the first half of this year, it is certainly putting the effort in. “We are stepping up our investments in R&D beyond our plans announced in April,” said Hubertus von Baumbach, chairman of Boehringer’s board, though he did not say exactly how much it would be spending.

Key Takeaways

  • Boehringer’s first-half drug sales totaled €10.3bn, growing by 9.3% year-over-year when adjusted for currency.

Still, the group has begun five new clinical trials in cardiometabolic diseases, mental health and oncology since the start of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.